antibodies, neoplasm

Phase 1a dose escalation study of ivonescimab (AK112/SMT112), an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors
Sophia Frentzas, Anna Rachelle Austria Mislang, Charlotte Lemech, Adnan Nagrial, Craig Underhill, Wenjing Wang, Zhongmin Maxwell Wang, Baiyong Li, Yu Xia, Jermaine I G Coward

Journal for ImmunoTherapy of Cancer Apr 2024, 12 (4) e008037; DOI: 10.1136/jitc-2023-008037
Regression of EGFR positive established solid tumors in mice with the conditionally active T cell engager TAK-186
Danielle E Dettling, Eilene Kwok, Lucy Quach, Aakash Datt, Jeremiah D Degenhardt, Anand Panchal, Pui Seto, Jessica L Krakow, Russell Wall, Brian J Hillier, Ying Zhu, Maia Vinogradova, Robert B DuBridge, Chad May

Journal for ImmunoTherapy of Cancer Jun 2022, 10 (6) e004336; DOI: 10.1136/jitc-2021-004336
Development of therapeutic monoclonal antibodies against DKK1 peptide-HLA-A2 complex to treat human cancers
Jianfei Qian, Qiang Wang, Liuling Xiao, Wei Xiong, Miao Xian, Pan Su, Maojie Yang, Chuanchao Zhang, Yabo Li, Ling Zhong, Siddhartha Ganguly, Youli Zu, Qing Yi

Journal for ImmunoTherapy of Cancer Jan 2024, 12 (1) e008145; DOI: 10.1136/jitc-2023-008145
Randomized, open-label, phase II, biomarker study of immune-mediated mechanism of action of neoadjuvant subcutaneous trastuzumab in patients with locally advanced, inflammatory, or early HER2-positive breast cancer—Immun-HER trial (GOIRC-01-2016)
Benedetta Pellegrino, Chiara Tommasi, Olga Serra, Stefania Gori, Elisabetta Cretella, Massimo Ambroggi, Antonio Frassoldati, Giancarlo Bisagni, Chiara Casarini, Emilio Bria, Luisa Carbognin, Elena Fiorio, Antonella Mura, Claudio Zamagni, Lorenzo Gianni, Alberto Zambelli, Filippo Montemurro, Michele Tognetto, Renata Todeschini, Gabriele Missale, Nicoletta Campanini, Enrico Maria Silini, Giuseppe Maglietta, Antonino Musolino

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (11) e007667; DOI: 10.1136/jitc-2023-007667
Single-cell RNA-sequencing atlas reveals an FABP1-dependent immunosuppressive environment in hepatocellular carcinoma
Weiwei Tang, Guangshun Sun, Gu-Wei Ji, Tingting Feng, Qian Zhang, Hengsong Cao, Wenhao Wu, Xiaoyi Zhang, Chuan Liu, Hanyuan Liu, Tian Huang, Li Liu, Yongxiang Xia, Xuehao Wang

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (11) e007030; DOI: 10.1136/jitc-2023-007030
First-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1)
Sophie Postel-Vinay, Vincent K Lam, Willeke Ros, Todd M Bauer, Aaron R Hansen, Daniel C Cho, F Stephen Hodi, Jan H M Schellens, Jennifer K Litton, Sandrine Aspeslagh, Karen A Autio, Frans L Opdam, Meredith McKean, Neeta Somaiah, Stephane Champiat, Mehmet Altan, Anna Spreafico, Osama Rahma, Elaine M Paul, Christoph M Ahlers, Helen Zhou, Herbert Struemper, Shelby A Gorman, Maura Watmuff, Kaitlin M Yablonski, Niranjan Yanamandra, Michael J Chisamore, Emmett V Schmidt, Axel Hoos, Aurelien Marabelle, Jeffrey S Weber, John V Heymach

Journal for ImmunoTherapy of Cancer Mar 2023, 11 (3) e005301; DOI: 10.1136/jitc-2022-005301
Targeting tumor vasculature to improve antitumor activity of T cells armed ex vivo with T cell engaging bispecific antibody
Jeong A Park, Madelyn Espinosa-Cotton, Hong-fen Guo, Sebastien Monette, Nai-Kong V Cheung

Journal for ImmunoTherapy of Cancer Mar 2023, 11 (3) e006680; DOI: 10.1136/jitc-2023-006680
Ligufalimab, a novel anti-CD47 antibody with no hemagglutination demonstrates both monotherapy and combo antitumor activity
Tailong Qu, Tingting Zhong, Xinghua Pang, Zhaoliang Huang, Chunshan Jin, Zhongmin Maxwell Wang, Baiyong Li, Yu Xia

Journal for ImmunoTherapy of Cancer Nov 2022, 10 (11) e005517; DOI: 10.1136/jitc-2022-005517
Patient-derived Siglec-6-targeting antibodies engineered for T-cell recruitment have potential therapeutic utility in chronic lymphocytic leukemia
Matthew G Cyr, Maissa Mhibik, Junpeng Qi, Haiyong Peng, Jing Chang, Erika M Gaglione, David Eik, John Herrick, Thomas Venables, Scott J Novick, Valentine V Courouble, Patrick R Griffin, Adrian Wiestner, Christoph Rader

Journal for ImmunoTherapy of Cancer Nov 2022, 10 (11) e004850; DOI: 10.1136/jitc-2022-004850
Suitability of tumor-associated antibodies as predictive biomarker for response to immune checkpoint inhibitors in patients with melanoma: a short report
Karlijn de Joode, Sharon Veenbergen, Claudia Kransse, Dian Kortleve, Reno Debets, Ron H J Mathijssen, Arjen Joosse, Marco W J Schreurs, Astrid A M Van der Veldt

Journal for ImmunoTherapy of Cancer Feb 2023, 11 (2) e006467; DOI: 10.1136/jitc-2022-006467

Main menu

antibodies, neoplasm

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

antibodies, neoplasm

Pages